Peptide library › Brain & nerves
NNZ-2591
Experimental oral medicine studied for rare genetic brain conditions such as Phelan-McDermid and Angelman syndromes.
What people use it for
- Phelan-McDermid syndrome (in trials)
- Angelman and Pitt Hopkins syndromes (in trials)
What NNZ-2591 does in the body
A synthetic version of cyclic glycine-proline, a natural molecule involved in regulating IGF-1 in the brain.
Strength of evidence
Limited: open-label Phase 2 studies reported improvements; a placebo-controlled Phase 3 trial is under way.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Generally mild in early trials
- Long-term safety unknown
Who should avoid it or take extra care
- Not available outside research
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
Investigational. Not approved by the FDA.
How it's taken
Route: Liquid by mouth (in trials)
How long it lasts (half-life): Not well established in published data
Keep track of NNZ-2591 privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open NNZ-2591 in Fiala How to installMore in Brain & nerves
- TrofinetideFirst approved treatment for Rett syndrome, a rare genetic brain condition; taken by mouth as a liquid.
- DavunetideExperimental nasal-spray peptide studied to protect brain cells, mainly in progressive supranuclear palsy.
- ZiconotideNon-opioid painkiller made from cone snail venom, given by a pump into the spinal fluid for severe chronic pain.